BIOMAT Database Logo BIOMAT Database Logo

Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. 1983

P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag

A double blind controlled trial of Becotide (beclomethasone diproprionate) inhalations was carried out for treating cystic fibrosis patients with chronic P. aeruginosa lung infection to determine its efficacy and safety. The aim of the treatment was to diminish the inflammatory response in the lungs of these patients, a response which is initiated by an allergic type III reaction. Pulmonary inflammation was evaluated by measurements of proteolytic activity, albumin concentration and immune complex activity in the sputum sol-phase before, during, and after the 16 weeks the trial lasted. 26 cystic fibrosis patients participated (13 received Becotide and 13 placebo) and the results showed that local steroids have no effect on the inflammatory response in the lungs of cystic fibrosis patients with chronic P. aeruginosa lung infection. No adverse effects were demonstrated. There was, however, a significant increase in the inflammatory parameters for all 26 cystic fibrosis patients when the trial period was over, compared to the insidious pulmonary destruction which takes place in the lungs of these patients, and it corresponded to a significant decrease (p less than 0.05) in forced vital capacity which took place at the same time. Therefore, chronic P. aeruginosa lung infection in these patients should be treated as efficiently as possible.

UI MeSH Term Description Entries
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D008297 Male Males
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females

Related Publications

P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection.
February 1978, Acta pathologica et microbiologica Scandinavica. Section C, Immunology,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
January 2014, PloS one,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Longitudinal study of antibody response to lipopolysaccharides during chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
September 1988, Infection and immunity,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection.
January 1999, Mediators of inflammation,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection.
February 1992, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.
October 1990, Infection and immunity,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis.
October 1983, Infection and immunity,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Sputum sol-phase proteins and elastase activity in patients with cystic fibrosis.
February 1984, European journal of respiratory diseases,
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
Eosinophil cationic protein in sputum from cystic fibrosis patients with Pseudomonas aeruginosa infections.
November 1994, Lancet (London, England),
P O Schiøtz, and M Jørgensen, and E W Flensborg, and O Faerø, and S Husby, and N Høiby, and S V Jacobsen, and H Nielsen, and S E Svehag
The host inflammatory response prior to death in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection.
November 1993, Respiratory medicine,
Copied contents to your clipboard!